Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer

<div>Cell uptake studies using human lung cancer A449 (αvβ3-positive) and NIH-3T3 (αvβ3-negative). Blocking studies using a 500-fold excess of unlabeled peptides confirmed receptor-specific uptake.</div>

Contrast Media & Molecular Imaging

fig7

Figure 7

Figure 7: Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer

Figure 7 | Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic RGD Peptide as an Early Diagnostic Agent for Overexpressed αvβ3 Integrin Receptors in Non-Small-Cell Lung Cancer 